Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Post by Jkj193741on Jul 02, 2018 8:48am

201 Views

Post# 28258459

WONDER WHERE THIS STUFF COMES FROM?

FROM MOMMAHOTSTUFF:
Analysts expect Resverlogix Corp. (TSE:RVX) to report $-0.08 EPS on July, 24.They anticipate $0.07 EPS change or 46.67% from last quarter’s $-0.15 EPS. The stock decreased 0.40% or $0.01 during the last trading session, reaching $2.46. About 180,441 shares traded or 18.90% up from the average. Resverlogix Corp. (TSE:RVX) has 0.00% since July 1, 2017 and is . It has underperformed by 12.57% the S&P500.

Bullboard Posts

Canopy Growth prepares for U.S. expansion with new acquisitions